ORY-1001 | B1957

ORY-1001 is a potent and selective inhibitor of LSD1 (IC₅₀ < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.

ORY-1001 is a potent and selective inhibitor of LSD1 (IC₅₀ < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.

B1957 | ORY-1001 DataSheet

Alternate Name/Synonyms: N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, dihydrochloride; RG-6016

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1431326-61-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₅H₂₄Cl₂N₂

Molecular Weight: 303.27

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~7 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent and selective LSD1 inhibitor

MDL Number: N/A

PubChem CID: 71664305

SMILES: C1CC(CCC1N)NC2CC2C3=CC=CC=C3.Cl.Cl

InChi: InChI=1S/C15H22N2.2ClH/c16-12-6-8-13(9-7-12)17-15-10-14(15)11-4-2-1-3-5-11;;/h1-5,12-15,17H,6-10,16H2;2*1H/t12?,13?,14-,15+;;/m0../s1

InChi Key: UCINOBZMLCREGM-RNNUGBGQSA-N